Angioimmunoblastic Lymphadenopathy With Dysproteinemia - 29 Studies Found
| Recruiting |
: Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study :
|
| Recruiting |
: Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma :
|
| Completed |
: RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas :
: Drug: RAD001 (Everolimus) Phase I Level 1: RAD001 2.5 mg PO daily D1-14 + CHOP Level 2: RAD001 5 mg PO d |
| Active, not recruiting |
: Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma :
: Drug: carfilzomib Given IV Other Names: |
| Recruiting |
: Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma :
|
| Recruiting |
: VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma :
: |
| Recruiting |
: Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma :
|
| Recruiting |
: CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL :
|
| Recruiting |
: CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma :
|
| Terminated |
: Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma :
|